BioRestorative Therapies

BioRestorative Therapies (NASDAQ: BRTX) is a clinical-stage biotech company that is developing cell-based therapies to treat chronic lumbar disc disease and metabolic conditions such as obesity and diabetes. The company is focusing on developing BRTX-100, its lead therapeutic candidate for the...

BioRestorative Therapies Inc. (NASDAQ: BRTX) (“BioRestorative”) is a clinical-stage biotech company that is developing cell-based therapies to treat chronic lumbar disc disease and metabolic conditions such as obesity and diabetes. The company is focusing on developing BRTX-100, its...

Chronic back pain is a significant issue in the United States, affecting millions of individuals annually. According to experts, up to 80% of the population will experience back pain at some point. Back pain can exist alone without nerve involvement and oftentimes, this is the most painful type of...

Valuations, competitive landscape and market opportunity are fundamental characteristics in evaluating investment decisions. Insider buying – the “smart money” – can also be an indicator to evaluate the potential performance of a company. BioRestorative Therapies Inc. (...

Chronic back pain is a significant issue in the United States, affecting millions of individuals annually. According to the National Institute of Neurological Disorders and Stroke, approximately 80% of adults will experience back pain at some point. BioRestorative Therapies Inc. (NASDAQ: BRTX) (...

BioRestorative Therapies Inc. (NASDAQ: BRTX) (“BioRestorative”), a clinical-stage company specializing in stem cell-based therapies, has announced that it has been granted a license by the New York State Department of Health to operate as a tissue bank. The license enables...

BioRestorative Therapies Inc. (NASDAQ: BRTX) has received a unanimous recommendation to proceed in its Phase 2 clinical trial for chronic lumbar disc disease, BRTX-100. The independent review body Data Safety Monitoring Board (DSMB) which is overseeing dose and safety related issues during the...

Once a lesser-known health condition, now a problem crippling millions of people around the world: metabolic syndrome is unfortunately on the rise. Due to the increasing sedentary lifestyle of screens and phones, a highly-processed diet, and a combination of other external factors like stress and...

Dr. Jason Lipetz, MD, Physiatrist & Head of Spine Medicine at Northwell Health, was recently interviewed by Benzinga. Dr. Lipetz is currently assisting BioRestorative Therapies, Inc (NASDAQ: BRTX) in phase 2 trials of a novel therapy for degenerative disc disease, BRTX-100. BioRestorative...

Brown Adipose-Derived Stem Cell (BADSC) therapy has emerged as a groundbreaking innovation in regenerative medicine, capturing the attention of scientists, clinicians and investors alike. BADSC therapy is a novel and proprietary form of regenerative medicine that is used to address several medical...

BioRestorative Therapies Inc (NASDAQ: BRTX) is expanding its ThermoStem® intellectual property portfolio for treatments targeting obesity, diabetes and other indications related to metabolic syndrome with another patent notice of allowance from the United States Patent Office, adding to...

Successful Autologous Cell-Based Therapies Autologous cell based therapies are personalized therapies using your own cells to target a disease or disorder. Personalized therapies targeting cancer such CAR-T cell therapies have generated impressive clinical results with complete remission rates in B...

Metabolism is the chemical process whereby the body produces energy from food. By breaking down carbohydrates and fats into sugars, the cells access fuel that can be used or stored via the liver or body fat. A metabolic disorder can occur when the body's chemical reactions become abnormal. This...

Lance Alstodt, Chairman and CEO of BioRestorative Therapies, Inc. (NASDAQ: BRTX), was recently interviewed by Benzinga.  BioRestorative Therapies is a cell therapy company that is developing two primary platform technologies. They are harnessing cutting-edge technology in stem cell research to...

BioRestorative Therapies (NASDAQ: BRTX), a clinical-stage biotechnology company focused on stem cell-based therapies, announced on the 8th of February that the European Patent Office had issued a notice of allowance for a patent application related to its metabolic ThermoStem® program. The...